Shanli Chen, Sudan Fang, Yang Zhou, Zhiwei Huang, Shujuan Yu, Dan Chen, Zhiyou Wang, Yanyan Xu, Peiwen Liu, Yongkun Li, Wei Lin, Longguang Jiang, Cai Yuan, Mingdong Huang
AIMS: Alteplase is a cornerstone thrombolytic agent in clinical practice, but presents a potential bleeding risk. Stroke patients need pre-screening to exclude hemorrhagic stroke before using Alteplase. In this study, we develop a new thrombolytic agent citPA5, characterized by an enhanced safety profile and minimal bleeding tendency. METHODS AND RESULTS: A clot lysis agent, named citPA5, is developed based on rtPA with point mutations to completely suppress its proteolytic activity in the absence of fibrin...
March 28, 2024: Cardiovascular Research